InvestorsHub Logo
Followers 0
Posts 13
Boards Moderated 0
Alias Born 03/19/2020

Re: None

Tuesday, 07/07/2020 10:07:28 AM

Tuesday, July 07, 2020 10:07:28 AM

Post# of 345952
“With cash reserves in place, we are now planning to quickly prioritize key programs in our pipeline,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “The world continues to suffer from the coronavirus pandemic, both in lives lost and economic devastation. We steadfastly believe that Brilacidin could play a significant role in treating this highly contagious and deadly virus. Steps have begun with the Contract Development and Manufacturing Organization (CDMO) in preparation for upcoming manufacture of the drug product for COVID-19 clinical trial use, to be followed by interactions with relevant Health Authorities to obtain input and guidance on trial design.”

http://www.ipharminc.com/press-release/2020/7/7/in-vitro-testing-of-innovation-pharmaceuticals-brilacidin-for-covid-19-shows-consistent-anti-sars-cov-2-efficacy-manufacturing-preparation-underway-for-covid-19-clinical-trial



Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News